Altimmune to Participate at Two Upcoming Conferences
2024年5月1日 - 8:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that Dr. Scott Harris, Chief Medical
Officer at Altimmune, will present on behalf of the Company at the
following two upcoming conferences:
- BTIG Obesity Health Forum (Virtual
Conference)Title: Emerging Therapeutics
PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern
Time
- GLP-1-Based Therapeutics Summit (Philadelphia,
PA)
- Title: Focusing on the Use of GLP-1s in
Treating MASH & Fatty Liver DiseaseWednesday, May 15,
2024Presentation at 10:00 am Eastern Time
- Title: Attaining Product Differentiation
through Improved Patient Segmentation & EfficiencyThursday, May
16, 2024Presentation at 1:30pm Eastern Time
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on
LinkedInFollow @AltimmuneInc on
Twitter
Altimmune Investor Contact:Richard
EisenstadtChief Financial OfficerPhone:
240-654-1450reisenstadt@altimmune.com
Investor Contact:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 4 2024 まで 5 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 5 2023 まで 5 2024